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Introduction
Despite advances in pharmacologic and device therapies, heart 
failure is one of the foremost causes of hospitalization in the United 
States, accounting for high morbidity, mortality, and increased burden 
to health care cost utilization.  It is estimated that nearly 6 million 
Americans are currently affected by heart failure, a number that is 
expected to reach 8 million by 20301.  Studies have shown that cardiac 
resynchronization therapy (CRT) improves the quality of life, decreases 
heart failure hospitalization, reduces left ventricular dimensions and 
overall mortality in patients left ventricular ejection fraction (LVEF) 
≤ 35%, NYHA functional class I-III and wide QRS in addition to 
guideline-directed medical therapy2-4. 
Given the limitations of organ availability, heart transplantation 
is not always the best therapeutic option in patients with ends stage 
heart failure.  Left ventricular assist device (LVAD) has been a viable 
alternative and has been increasingly used as destination therapy 
(DT), bridge to transplant (BT), and bridge to recovery in end-stage 
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Abstract
Introduction: Whether cardiac resynchronization therapy (CRT) continues to augment left ventricular remodeling in patients with the 
continuous-flow left ventricular assist device (cf-LVAD) remains unclear.   
Methods: We performed a systematic review and meta-analysis of all clinical studies examining the role of continued CRT in end-stage 
heart failure patients with cf-LVAD reporting all-cause mortality, ventricular arrhythmias, and ICD shocks. Mantel-Haenszel risk ratio (RR) 
random-effects model was used to summarize data.  
Results: Eight studies (7 retrospective and 1 randomized) with a total of 1,208 unique patients met inclusion criteria. There was no 
difference in all-cause mortality (RR 1.08, 95% CI 0.86 – 1.35, p = 0.51, I2=0%), all-cause hospitalization (RR 1.01, 95% CI 0.76-1.34, p = 
0.95, I2=11%), ventricular arrhythmias (RR 1.08, 95% CI 0.83 – 1.39, p = 0.58, I2 =50%) and ICD shocks (RR 0.87, 95% CI 0.57 – 1.33, p = 
0.52, I2 =65%) comparing CRT versus non-CRT.  Subgroup analysis demonstrated significant reduction in ventricular arrhythmias (RR 0.76, 
95% CI 0.64 – 0.90, p = 0.001) and ICD shocks (RR 0.65, 95% CI 0.44 – 0.97, p = 0.04) in “CRT on” group versus “CRT off” group. 
Conclusion: CRT was not associated with a reduction in all-cause mortality or increased risk of ventricular arrhythmias and ICD shocks 
compared to non-CRT in cf-LVAD patients. It remains to be determined which subgroup of cf-LVAD patients benefit from CRT.The findings of 
our study are intriguing, and therefore,larger studies in a randomized prospective manner should be undertaken to address this specifically.
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heart failure patients on guideline-directed medical therapy and 
CRT if indicated5.However, whether CRT continues to augment 
left ventricular remodeling in patients with end-stage heart failure on 
LVAD remains unclear.  Based on current available literature, there 
are no strict guidelines (limited to consensus statement regarding 
device and arrhythmia management in patients with LVAD)6 on 
continued left ventricular pacing (as a part of CRT) in advanced heart 
failure patients with continuous-flow left ventricular assist device 
(cf-LVAD).  Therefore, we performed a systematic review and meta-
analysis of all the clinical studies examining the role of continued 
cardiac resynchronization therapy in end-stage heart failure patients 
with cf-LVAD. 
Search Strategy
The reporting of this systematic review and meta-analysis complies 
with PRISMA (Preferred Reporting Items for Systematic Reviews and 
Meta-Analysis) guidelines (Supplement Table 1)7 and prospectively 
enrolled in the PROSPERO database. 
We searched PubMed, Clinicaltrials.gov,the Web of Science, 
EBSCO database, Google Scholar, Cochrane Central Registry, and 
various major scientific conference sessions (American College of 
Cardiology, American Heart Association, Heart Rhythm Society, 
European Society of Cardiology and Cardiostim) for published 
abstracts and manuscripts until May 30, 2020. We used the following 
keywords and medical subject heading: “left ventricular assist device,” 
LVAD”, “CRT”, “cardiac resynchronization therapy”.
Study selection and data extraction 
We included randomized clinical trials, prospective and retrospective 
studies. Considering the paucity of evidence, we decided to include 
abstracts. Any meta-analysis, review articles, studies with no 
comparator arm,or studies involving pulsatile flow LVAD (pf-LVAD) 
were excluded from our analysis.  The data from included studies were 
extracted using a standardized protocol and a data extraction form. 
Any discrepancies between the two investigators were resolved through 
consensus and arbitration with the co-senior investigators (D.L and 
J.G).The following data were extracted: author name, study design, 
publication year, follow-up duration, number of patients, age, gender, 
biventricularpercent pacing, comorbidities, etiology of cardiomyopathy, 
INTERMACS score, indications of cf-LVAD, left ventricular ejection 
fraction (LVEF), left ventricular end-diastolic dimension (LVEDD), 
ventricular arrhythmias, implantable cardioverter-defibrillator (ICD) 
shocks, medications, and outcomes.  The Newcastle Ottawa Risk bias 
assessment tool was used to appraise the quality of non-randomized 
studies (Supplement Table2).  The Cochrane – Risk bias assessment 
tool was used to appraise the quality of a randomized controlled trial 
(Supplement Table3).
Clinical outcomes
The primary outcome of our study was – (i) all-cause mortality (ii) 
all-cause hospitalization (composite of heart failure and ventricular 
arrhythmia related hospitalization), (iii) ventricular arrhythmias,and 
(iv) appropriate ICD shocks between the CRT and non-CRT groups 
with cf-LVAD.
  
Subgroup analysis was performed comparing “CRT on” versus 
“CRT off ” (to assess long term effect sequela ofwide QRS in cf-LVAD 
patients, if any).  Outcomes studied were all-cause hospitalizations per 
patient, ventricular arrhythmia, and appropriate ICD shocks. 
Statistical analyses
The meta-analysis was performed using a meta-package for R 
version 4.0 and Rstudio version 1.2. Mantel-Haenszel risk ratio (RR) 
random-effects model (DerSimonian and Laird method) was used 
to summarize data between the two group8. For continuous variables, 
weighted mean difference (WMD) was calculated to evaluate the 
difference in clinical outcomes between relevant subgroups in patients 
with cf-LVAD.  Heterogeneity of effects among the included studies 
was assessed by Higgins I-squared (I2) statistic9. A value of I2 of 0–25% 
represented insignificant heterogeneity, 26–50% represented low 
heterogeneity, 51–75% represented moderate heterogeneity, and more 
than 75% represented high heterogeneity, as set forth by the Cochrane 
Collaboration. Publication bias was visually and formally assessed 
using funnel plots.  A two-tailed p < 0.05 was considered statistically 
significant for all analyses.
Figure 1: Flow Diagram illustrating the systematic search of studies
Figure 2: Cardiac Resynchronization Therapy in end-stage heart failure patients with cf-LVAD
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424.36±425.25 days.  Table 1 summarizes the baseline characteristics 
of the included trials in our meta-analysis.  Studies by Gopinathannair 
et al.(published in 2015 18and 201819) enrolled patients from the same 
institution and overlapping years.  Therefore, we only included the 
study by Gopinathannair et al published in 2019, as it was more 
contemporary of the three16. Patients in the “CRT off ” subgroup were 
included in the non-CRT group for the overall analysis. Studies by 
Gopinathannairet al and Roukuz et al enrolled patients from the same 
Results 
Search results
A total of 280 citations were identified (Figure 1) during the initial 
search.  Two hundred seventy-two records were excluded.  After a 
detailed evaluation of these studies, eight articles: 7retrospectives10-16 
and 1 randomized clinical trial17 ultimately met the inclusion 
criteria, constituting 1,208 unique patients with a mean follow-up of 
Table 1: Baseline characteristics of the studies included in our analysis
Study Schleifer et al Richardson et al Roukoz et al Choi et al Kutyifa et al Mai et al Rao et al Gopinathannair 
et al
















99 (94-99) 96 ± 5.3 96 ± 5
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N 39 26 20 21 251 44 22 13 61 130 40 47 135 118 280 106
Age
Mean ± SD (years)
62±13 62±14 . . 60±0.8 63±1.8 56±12 58.9±9.7 55.3±27 57.7 54.4 60±12 60±13
Males
(N, %)
31 (79) 24 (92) . . 208 
(82.9)
37 (84.1) 29 (total) 
(82.85)

































17±6 18±6 . . 15.8±5.8 16.6±7.7 . . 20 (total) 16.9 19.1 16±6 16±6
LVEDD-mm
Mean ± SD












18 (46) 8 (31) . . 115 
(45.7)










141±27 138±43 . . 160±29 152±29 . . . . 159±29 155±26
Beta-blockers
(N, %)




230 (82) 91 (86)
ACEi or ARB’s
(N, %)








. . . . 56 (22.5) 8 (19.1) . . . . . .
Nitrates
(N, %)
. . . 35 (14.1) 4 (9.5) . . . . . .
Hydralazine
(N, %)








. . . 104 (77) 76 (64) 112 
(40)
36 (34)
ACEi: Angiotensin-converting enzyme inhibitor, ARB: Angiotensin receptor blocker
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In studies comparing “CRT on” vs “CRT off ”10,11, all-cause 
hospitalization per patient was not significantly different between 
“CRT on” versus “CRT off ” in cf-LVAD patients (WMD -1.07,  95% 
CI -3.97 – 1.82, p = 0.47, I2=63%) (Figure 5B).
Ventricular arrhythmias
The data forthe incidence ofventricular arrhythmias after cf-LVAD 
was available in 5 trials10,12,14-16.The CRT group was not associated with 
increased risk of ventricular arrhythmias as compared to the non-CRT 
group in cf-LVAD patients (44.76% vs.40.32%, RR 1.08, 95% CI 0.83 
– 1.39, p=0.58).Moderateheterogeneity was observed between trials 
(I2 =50%) (Figure 6).
When comparing “CRT on” vs.“CRT off ”10,11, “CRT on” group 
was associated with a lower incidence of ventricular arrhythmias as 
compared to “CRT off ” group in cf-LVAD patients (57.9% vs. 75.7%, 
RR 0.76, 95% CI 0.64 – 0.90, p = 0.001).  No heterogeneity was 
observed between trials (I2 =0%) (Supplement Figure 1).
Appropriate ICD shocks
Four studies reported data on the ICD shocks10,15-17.  The incidence 
of ICD shocks did not differ between CRT and non-CRT group in 
cf-LVAD patients (35.86% vs 33.58%, RR 0.87, 95% CI 0.57 – 1.33, 
p = 0.52).  Moderate heterogeneity was observed between trials (I2 
=65%). (Figure 7).
In studies comparing “CRT on” versus “CRT off ”10,11,17, “CRT 
on” group was associated with a lower incidence of ICD shocks as 
compared to “CRT off ” in cf-LVAD patients (33.87% vs. 47.25%, RR 
0.65, 95% CI 0.44 – 0.97, p = 0.04).  Mild heterogeneity was observed 
between trials (I2 =28%). (Supplement Figure2).
Discussion 
The main findings in this analysis are: (1) all-cause mortality and 
hospitalizations did not differ between CRT and non-CRT groups 
institution and overlapping years; hence we included Gopinathannair 
et al for comparing CRT versus non-CRT and Roukuz et al for 
“CRT on”vs“CRT off ”.While comparing overall analysis (CRT vs. 
non-CRT), Roukuz et al was excluded due to overlapping data with 
Gopinathannair et al. 
Study characteristics 
Of eight studies included in our analysis, five studies evaluated CRT 
versus non-CRT in cf-LVAD patients (CRT = 597 patients, non-
CRT = 505 patients) 12-16; while 3 studies evaluated “CRT on” versus 
“CRT off ” in cf-LVAD patients (“CRT on” = 310 patients, “CRT off ” 
= 91 patients)10,11,17.Overall, the mean age of the patients was 58.04 
± 12.84years.  Bridge to transplantation (BTT)as the indication for 
LVAD placement was available in three trials (n = 341, 45.7%).10,11,16
Data on antiarrhythmic drugs was available only in 4 studies, with 
51% patients (232/454) in CRT vs 50% patients (125/250) in non-
CRT group (p=0.81); while 58.27% patients (169/290) in “CRT on” 
vs 51.42% (36/70) in “CRT off ” sub-group (p=0.35) (Table 1 and 
Figure 3).
Outcomes (Figure 4-6, Supplement figure 1-2)
All-cause mortality 
The data for all-cause mortality was available in 3 trials13,15,16.The 
presence of CRT was not associated with any difference in all-cause 
mortalityas compared to non-CRT in patients with cf-LVAD (30.67% 
vs.27.4%, RR 1.08, 95% CI 0.86 – 1.35, p=0.51).  No heterogeneity was 
observed between trials (I2 =0%)(Figure 4). 
All-cause hospitalization
Two studies reported data on all-cause hospitalization15,17.  Rates 
of hospitalizationwere not significantly different between CRT and 
non-CRT group in cf-LVAD patients (67.10% vs. 68.88%, RR 1.01, 
95% CI 0.76-1.34, p = 0.95, I2 =11%) (Figure 5A).
Figure 4:
All-cause mortality.The Forest plot shows the outcomes of the 
individual trials as well as the aggregate.  Point estimates to the 
left favors CRT.  The funnel plot demonstrates no publication bias.
Figure 3: Antiarrhythmic drug use in end-stage heart failure patients on cf-LVAD.
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by the improvement of electrical dyssynchrony resulting in improved 
mechanical synchrony in a setting of wide QRS.  Acute LV unloading, 
change in LV fiber orientation/cardiac chambers from LVAD 
inflow cannula, and limited pulsatility of LV might counterpoise the 
hemodynamic effect and long-term sequelae observed with CRT 16,23. 
Fourth, improved patient care, care transition teams, and improvement 
in LVAD design (over the last decade), resulting in enhanced patient 
survival, might offset the effects of biventricular pacing.
Studies have shown that CRT may exhibit proarrhythmic 
effect 24[thought to be due to differential activation and creation 
of two different wavefronts (from RV and LV pacing), resulting 
in a unidirectional functional block and initiating reentrant 
arrhythmias], with an increased risk of ventricular arrhythmias in 
CRT non-responders25.Besides, ventricular arrhythmia prior to LVAD 
implantation is an independent predictor of recurrent arrhythmia 
after LVAD implantation26.  In our pooled analysis, although the non-
CRT group had a lower incidence of ventricular arrhythmias and ICD 
shocks, it did not reach statistical significance. The findings of our study 
corroborate with the study from Gopinathannair et al. demonstrating 
no significant association between QRS duration or RV pacing or LV 
pacing on long term outcomes (i.e.,hospitalization or development of 
ventricular arrhythmias)16.  
It is well known that a wide QRS (left bundle block or right bundle 
branch block) and resultant inter/intraventricular dyssynchrony 
is associated with adverse clinical outcomes in patients with heart 
failure27,28.  Acute LV unloading, thereby reducing wall stress from cf-
LVAD,surpasses the potential electrical remodeling benefit derived 
from either narrow QRS or biventricular pacing.  However, in subgroup 
analysis, there was a statistically significant reduction in episodes of 
ventricular arrhythmias and ICD shock in “CRT on” group versus 
“CRT off ”.  The precise pathophysiology of the observed finding 
remains unclearand could represent Type 1 error.  Also, there was 
in end-stageheart failure patients with cf-LVAD; (2) no reduction in 
ventricular arrhythmias and ICD shocks was observed; (3) Significant 
reduction in ventricular arrhythmias and ICD shocks was observed 
in cf LVAD patients with “CRT on” as compared to “CRT off ” 
(Figure 2).  The findings of our study are important clinically and 
indicate that cf LVAD patients with active CRT did not derive any 
long term any benefit with continued LV pacing; however, there was 
significant reduction in ventricular arrhythmias and ICD shocks in 
cf-LVAD patients with “CRT on” versus “CRT off ”. Nonetheless, due 
to reduction in battery longevity requiring multiple procedures, risks 
and benefits must be judiciously contemplated. 
MADIT-CRT post hoc analysis demonstrated that patients with 
≥97% biventricular are at reduced risk of heart failure hospitalization 
and mortality as compared to patients with < 97% biventricular 
pacing20.  In addition, cf-LVAD improves overall survival in end-stage 
heart failure patient; however, the benefit of CRT in cf-LVAD may 
not be additive.Whether or not continued LV pacing post LVAD 
implantation for maximal LV remodeling remains controversial.There 
are several potential explanations for the findings observed in our study. 
First, lack of randomized clinical trials may have caused a selection 
bias towards sicker patients, resulting in no observed mortality benefit 
with CRT. Second, advanced heart failure patients on cf-LVAD are 
at increased risk of mortality from non-arrhythmic causes such as 
device infection, pump failure, or pump thrombosis, factors that may 
outweigh the net clinical benefits of CRT.  Third, hemodynamic effects 
observed with cf-LVAD might offset the electromechanical effects and 
the long-term sequelae seen with CRT.  The RV and LV shares oblique 
fibers within the interventricular septum, thereby augmenting RV 
contractility with LV contraction21,22.  With a decline in LV function, 
oblique septal fibers orient in a more transverse orientation due to 
spherical shaped LV (given volume overload), thereby reducing RV 
contractility.  Therefore, CRT (in non-LVAD patients) by reverse LV 
modeling may in turn improve septal fibers orientation and improve RV 
function.  It is worthwhile to notice that hemodynamic benefits of CRT 
in improvement on LV systolic function are predominantly mediated 
Figure 5:
All-cause hospitalization. (A) The Forest plot shows the outcomes 
of the individual trials as well as the aggregate.  Point estimates 
to the left favors CRT.  (B)  The forest plot shows all-cause 
hospitalization per patient was not significantly different between 
“CRT on” versus “CRT off” in cf-LVAD patients.  Point estimates to 
the left favor “CRT on”.  
Figure 6:
Ventricular arrhythmias.The Forest plot shows the outcomes of 
the individual trials as well as the aggregate.  Point estimates to 
the left favors CRT.  The funnel plot demonstrates no publication 
bias.
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undertaken to address this specifically.  
Because of the lack of definite clinical data assessing the role of 
CRT in LVAD patients, it remains controversial at this time regarding 
optimal device programming settings.  Therefore, in our clinical practice, 
we typically deactivate the LV pacing (and reprogram to minimize 
RV pacing unless otherwise pacer dependent) to preserve battery life 
and minimize generator changes19, which by themselves carry a risk 
of infections or anticoagulation related issues (pocket hematoma or 
LVAD pump thrombosis) in this high-risk population (Figure 8).
This systematic review and meta-analysis has several important 
limitations.First, patient selection bias due to limited data (retrospective 
nature of included studies and conference abstracts) could not be 
excluded.  Also, the trials that evaluated “CRT on” versus “CRT off ” 
had a small size and lacked sufficient statistical power to draw realistic 
conclusions.  Second, information on arrhythmia burden/morphology 
and its timing in relation to LVAD were obscure.  Third, variations in 
the LV lead position depending underlying anatomy and operator 
experience, device programming parameters in cf-LVAD patients 
were not well defined.  Fourth, QRS duration, change in QRS post 
LVAD, and change in LVEF was not available in all trials to thoroughly 
understand hemodynamic effects between CRT on and off groups. 
Fifth, data on antiarrhythmic and other medications, etiology of death 
(cardiac, or non-cardiac), generator changes, and LVAD/CRT related 
complications were not outlined in all trials.Finally,patient-level data 
to perform more detailed analyses are not available. 
Conclusion 
Cardiac resynchronization therapy was not associated with 
a reduction in all-cause mortality, increased risk of ventricular 
arrhythmias, and ICD shocks as compared to non-CRTin end-
stage heart failure patients with cf-LVAD. However, it remains to be 
determined which subgroup of cf-LVAD patients may benefit from 
cardiac resynchronization therapy.Future research should be directed to 
study the role of CRT in end-stage heart failure patients with cLVAD 
in a dedicated randomized controlled study.
Please Click for Supplemental Material
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